Considerations for Treatment Sequencing in LR-MDS

Thomas W. LeBlanc, MD, MA, discusses how existing challenges in treatment choices for low-risk myelodysplastic syndromes (LR-MDS) include limited access to newer therapies, patient-specific factors, and treatment sequencing complexities, and explores strategies to address these barriers, such as improving health care access, optimizing patient selection, and enhancing treatment guidelines.